Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9886034 | 0.84 | ALDH1A1 (0.39) | KDM4EKMT2AALDH1A1NPC1MAPT | |
| SCHEMBL8301886 | 0.83 | — | — | |
| SCHEMBL18122804 | 0.80 | KDM4E (0.59) | KDM4EKMT2AALDH1A1 | |
| SCHEMBL26431756 | 0.80 | SMN1; SMN2 (0.35) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL16887587 | 0.80 | ALDH1A1 (0.36) | SMN1; SMN2ALDH1A1MMP1MMP13 | |
| SCHEMBL15221367 | 0.78 | CYP3A4 (0.41) | KDM4EKMT2AALDH1A1MAPTCYP2C9 | |
| SCHEMBL23240873 | 0.78 | — | — | |
| SCHEMBL7806892 | 0.78 | KDM4E (0.40) | SMN1; SMN2KDM4EKMT2AALDH1A1MAPT | |
| SCHEMBL24047105 | 0.76 | — | — | |
| SCHEMBL7808381 | 0.76 | KMT2A (0.39) | SMN1; SMN2KDM4EKMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937262-B1 | COMPOSITION FOR USE IN TREATING GASTROINTESTINAL DYSMOTILITY | IPSEN PHARMA (FR) | 2019-05-08 | — | — | EP | disclosed |
| EP-2794634-B1 | PROCESS FOR THE SYNTHESIS OF GHRELIN ANALOGUES | IPSEN MFG IRELAND LIMITED (IE) | 2018-01-24 | — | — | EP | disclosed |
| US-20170362275-A1 | Growth Hormone Releasing Peptides | IPSEN PHARMA S.A.S. (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170304403-A1 | METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE | IPSEN PHARMA S.A.S. (FR) | 2017-10-26 | — | — | US | disclosed |
| US-20170137489-A1 | Process for the Synthesis of Therapeutic Peptides | IPSEN MANUFACTURING IRELAND LIMITED (IE) | 2017-05-18 | — | — | US | disclosed |
| US-20170037104-A1 | Composition and Methods for Stimulating Gastrointestinal Motility | IPSEN PHARMA S.A.S. (FR) | 2017-02-09 | — | — | US | disclosed |
| EP-1928489-B1 | ANALOGS OF GHRELIN | IPSEN PHARMA (FR) | 2014-03-26 | — | — | EP | disclosed |
| EP-2662087-A1 | Somatostatin vectors | IPSEN PHARMA (FR) | 2013-11-13 | — | — | EP | disclosed |
| EP-2083842-B1 | ANALOGS OF GHRELIN SUBSTITUTED AT THE N-TERMINAL | IPSEN PHARMA SAS (FR) | 2013-08-28 | — | — | EP | disclosed |
| WO-2013093639-A1 | PROCESS FOR THE SYNTHESIS OF THERAPEUTIC PEPTIDES | IPSEN MANUFACTURING IRELAND LIMITED (IE) | 2013-06-27 | — | — | WO | disclosed |
| EP-2130548-A2 | Growth Hormone Releasing Peptides | IPSEN PHARMA (FR) | 2009-12-09 | — | — | EP | disclosed |
| EP-1542716-B1 | GROWTH HORMONE RELEASING PEPTIDES | IPSEN PHARMA (FR) | 2009-11-04 | — | — | EP | disclosed |
| WO-2009020643-A2 | METHOD FOR INHIBITING INFLAMMATION AND PRE-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE | IPSEN PHARMA S.A.S. (FR) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008051421-A2 | PEPTIDE-CYTOTOXIC CONJUGATES | IPSEN PHARMA S.A.S. (FR) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008039415-A2 | ANALOGS OF GHRELIN SUBSTITUTED AT THE N-TERMINAL | IPSEN PHARMA S.A.S. (FR) | 2008-04-03 | — | — | WO | disclosed |
| WO-2007106385-A2 | USE OF A GHRELIN AGONIST TO IMPROVE THE CATABOLIC EFFECTS OF GLUCOCORTICOID TREATMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007041278-A2 | COMPOSITION AND METHODS FOR STIMULATING GASTROINTESTINAL MOTILITY | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007038678-A2 | ANALOGS OF GHRELIN | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2007-04-05 | — | — | WO | disclosed |
| WO-2004014415-A1 | GROWTH HORMONE RELEASING PEPTIDES | SOCIETE DE CONSEIL DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004009616-A2 | GHRELIN ANALOGS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304403-A1 | METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE | PROKR1, CCL2, PROKR2 | SMN1; SMN2 3709/4885KDM4E 4127/4885KMT2A 3660/4885 |
| US-20170037104-A1 | Composition and Methods for Stimulating Gastrointestinal Motility | GIPR, VIP, GRPR | SMN1; SMN2 1082/4885KDM4E 4383/4885KMT2A 3583/4885 |
| US-20170137489-A1 | Process for the Synthesis of Therapeutic Peptides | NPEPPS, DNPEP, QPCT | SMN1; SMN2 832/4885KDM4E 3660/4885KMT2A 3149/4885 |
| US-20170362275-A1 | Growth Hormone Releasing Peptides | GHRHR, THRB, PRLHR | SMN1; SMN2 4862/4885KDM4E 3541/4885KMT2A 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.